Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Per last 10K Koos himself owns 193M+
Zander owns 163M+
Who owns Zander? ??
Koos
So his stake is way deeper
Explanation of IP to be licensed from Weill-Cornell:
(Test Product shall be defined as a Patient-Derived Organoid on VascularNet (PDOV) for a specific tumor type)
Organoids Just Gained Their Missing Ingredient:
Functional Blood Vessels... VascularNet
THE CONTEXT: Organoids are a critical tool helping researchers study diseases like cancer to develop/test drugs. Formerly, organoid models didn't contain functional blood vessels, limiting their ability to accurately model disease.
THE STUDY: Scientists can now create organoids containing functional human blood vessels thanks to scientists led by Shahin Rafii, MD, of Weill Cornell Medicine.
THE IMPORTANCE: With the ability to generate organoids that contain functional blood vessels, researchers can now better model cancer biology and identify effective therapies.
*Shahin Rafii, MD; “We can now decipher how cancerous blood vessels acquire their abnormal features, permitting identification of new druggable targets for tumors.”
This is Ground-Breaking.
Excellent Words L&L!
Not in the 8K
Thank you HB
Unaware of that entry. Do not see it in the 8k or attached exhibits. Could you please direct me to such? thank you
Thank you
TMU The LOI has no definitive due date. There are multiple things yet to happen prior to any agreement. Both sides have written they have full rights of DD and for one, there must be a third party valuation of the 95% controlling interest of Canary prior to the yet-to-be-determined quantity of shares being issued for that value.
CAN'T STRESS THIS ENOUGH.. The higher the PPS 2 weeks prior to the agreement completion, the FEWER shares required to fill that value.
IMO Koos is gonna do things prior to the signing to RAISE share price significantly.
10K as well ??
Excellent Analysis
Sybleu S-1 8/17/20 both addresses apply.
I could see that :)
It's a 2021 Indoleamine 2,3 Dioxygenase 1 Industry Development History, Market Supply and Demand and Scale Analysis Report
Can't see that. Chemdiv's annual Total revenue is only about 15 to 16M.
800K is about 5% of that. Much more of the net. And I would have thought if they were going to be buying shares, they would have settled much earlier because they could have gotten shares in the triple zero range and gotten hundreds of millions more. Plus they are a CRO and constantly need cash for research.
THOUGHTS?
Do you think maybe middle level investment firms are accumulating?
BUY Vol outpacing SELL Vol
Maybe a CSO would be appointed as a 2nd director which would be one of the steps required in order to up-list to the OTCQB
Buy Vol 39,227,974 Sell Vol 44,778,466
Unlisted Volume 5,457,348
G'Nite Moon
Makes sense to me :)
Agreed. Every Major Pharma has known - in depth - about this Portfolio for a long time.
Thank You!
Well Said
Well said
Yessir
Regen / Lilly 8K 4-11-2016
https://www.otcmarkets.com/filing/html?id=11311054&guid=4lkwkKwg3i5If3h
I got me some Azuca. Highly recommend it.
Love that blue sky :)
A key catalyst in the 8K
Exhibit 10.2 Item 2
Chemdiv to Provide Documents and Information to Regen upon Payment. Upon payment of the amount set forth in paragraph 1 by Regen to Chemdiv, Chemdiv shall provide Regen with all results, compounds identified, and data generated by Chemdiv relative to its NR2F6 research conducted on behalf of or at the direction of Regen and/or Zander, together with specification of the means of conducting such research, including but not limited to protocols used in conducting such research. Ownership rights relating to the intellectual property reflected in such data, information, and documents shall become the property of Regen and Zander
https://sec.report/Document/0001607062-21-000349/#rgbp092421form8k.htm
According to this 8K it appears Regen/KCL own the majority.
https://www.otcmarkets.com/filing/html?id=15088630&guid=ubUwkHPOSV8QFth
Just chunkin' rocks :)
In 2014, healthcare company Baxter International, Inc., spun-off its biopharmaceuticals business Baxalta Incorporated. The separation was announced in March and was completed on July 1. Baxter shareholders received one share of Baxalta for each share of Baxter common stock held. The spin-off was achieved through a special dividend of 80.5% of the outstanding shares of Baxalta, with Baxter retaining a 19.5% stake in Baxalta immediately after the distribution.? Interestingly, Baxalta received a takeover offer from Shire Pharmaceuticals within weeks of its spin-off. Baxalta's management rebuffed the offer, saying it undervalued the company. The merger did eventually close in June 2016.
Oh I completely agree. But Koos is a serial entrepreneur
Why else would he get Sybleu's S1 complete prior to Regen's finances?
Maybe he transfers a couple patents to them, thus making it very attractive.
LoL that's funny
Seems the only requirement so far unmet to meet OTCQB status is having 2 Directors and an Audit Committee.
Hiring a CSO and designating that person a'Director' could provide such.
And I still kind of figure he'll eventually take Sybleu public.
Based on his "Obtain OTCQB listing for our SECURITIES on the OTC Market" statement.
I completely expect a significant Collaborative deal before EOY.